Docket: T-2105-16
Citation:
2017 FC 76
Ottawa, Ontario, January 20, 2017
PRESENT: The
Honourable Mr. Justice Gascon
BETWEEN:
|
UNILIN BEHEER
B.V. AND
|
FLOORING
INDUSTRIES LIMITED, SARL
|
Plaintiffs
|
and
|
TRIFOREST INC.,
JUNWU ZHANG
|
ZAIRONG FENG,
CONGYU ZHANG
|
AND MOLSON
INTERNATIONAL TRADING INC.
|
Defendants
|
PUBLIC ORDER AND REASONS
I.
Overview
[1]
By an amended notice of motion dated December
28, 2016, the Plaintiffs Unilin Beheer B.V. [Unilin] and Flooring Industries
Limited, Sarl [FIL] request three remedies from this Court. First, they apply
for a review of the execution of the ex parte Mareva injunction order [the
Mareva Injunction Order] issued by Mr. Justice LeBlanc on December 19, 2016 against
the Defendants Triforest Inc. [Triforest], Mr. Junwu Zhang, Ms. Zairong Feng
and Ms. Congyu Zhang [collectively, the Triforest Defendants], and a
declaration that this Mareva Injunction Order was lawfully executed. Second,
they seek to convert this Mareva Injunction Order into an interlocutory Mareva injunction
pursuant to Rule 373 of the Federal Courts Rules, SOR/98-106. Third,
they want to obtain an interlocutory injunction order against the Triforest Defendants
as well as the Defendant Molson International Trading Inc. [Molson] pursuant to
Rule 373 or, in the alternative and as the Defendants may elect, an order to deposit
into Court. The three aspects of the Plaintiffs’ motion are collectively
referred to as the Review Motion in this judgment.
[2]
The Plaintiffs claim that the Defendants are
infringing certain patents they hold with respect to laminate flooring
products. Laminate flooring is a multi-layer wood-based flooring product and
generally consists of multiple panels that are coupled together to cover a
floor surface.
[3]
The Plaintiffs contend that an interlocutory
Mareva injunction order should be issued by this Court against the Triforest
Defendants as there is genuine risk that the Triforest Defendants would remove
their liquid assets from Canada or dissipate them to render ineffective any
judgment of this Court. The Plaintiffs further submit that the Court should
also issue an interlocutory injunction order against all Defendants to prevent
them from continuing to manufacture, use, sell or import into Canada their
laminate flooring products until the questions of patent infringement and
validity are finally determined by this Court on the main action.
[4]
The Defendants respond that the Court should
dismiss the Plaintiffs’ request on the execution of the Mareva Injunction Order
as the Order was improperly obtained and is impossible to properly enforce. The
Defendants further submit that the Plaintiffs have failed to establish the
existence of a real risk that the Triforest Defendants have or will expatriate
or dissipate financial resources, let alone outside the normal course of
business and for the purpose of avoiding the possibility of a judgment.
Finally, the Defendants argue that the Court should not issue an interlocutory
injunction to restrain them from manufacturing, using, selling or importing
into Canada laminate flooring products that purportedly infringe the Plaintiffs’
patents as the Plaintiffs have failed to establish irreparable harm that cannot
be compensated financially.
[5]
There are three issues to be decided on this Review
Motion:
A. Was the Mareva Injunction Order lawfully executed?
B. Should the Mareva Injunction Order be converted into an interlocutory
Mareva injunction order?
C. Should the interlocutory injunction order sought by the Plaintiffs be
granted?
[6]
For the reasons that follow, the Plaintiffs’ Review
Motion is granted in part. I conclude that the Mareva Injunction Order was
lawfully executed in accordance with its terms and followed the applicable
procedural rules. However, I am not persuaded that the elements required to
issue an interlocutory Mareva injunction order are satisfied. This is because the
evidence obtained and provided by the Plaintiffs is not sufficient to demonstrate,
on a balance of probabilities, that there is a real risk of removal or
dissipation of assets in order to frustrate judgment. I am also not satisfied
that the tripartite test set forth in RJR-MacDonald Inc v Canada (Attorney
General), [1994] 1 S.C.R. 311 [RJR-MacDonald] for the issuance of
interlocutory injunctions is met, as the Plaintiffs have notably failed to
provide the required clear and non-speculative evidence to demonstrate, on a
balance of probabilities, that they will suffer irreparable harm if the injunction
is not granted.
II.
Background
A.
The parties
[7]
The Plaintiffs Unilin and FIL are sister
companies that are part of the Unilin Group. Unilin is a Netherlands-based
company and FIL is a Luxembourg company. The Unilin Group regroups companies
that are leading manufacturers of a variety of products in the building
materials industry, including laminate flooring products.
[8]
Traditionally, laminate flooring was installed
by coupling panels with each other using a simple tongue and groove joint secured
by an adhesive such as glue. The Unilin Group then developed a revolutionary
technology for joining panels of laminate floor products without the use of an
adhesive [the Glueless Locking Technology], and launched it in the market in
1997. The Glueless Locking Technology involves shaping the profiles of the
tongue and groove of the flooring panels such that they are “locked” when coupled together. The tongue and groove
of the flooring panels can be coupled together by rotation or lateral
displacement. The Glueless Locking Technology is protected throughout the world
by a vast portfolio of patents held by the Unilin Group.
[9]
Unilin owns the patent rights relating to the Glueless
Locking Technology and FIL is responsible for the licensing and enforcement of the
Unilin Group’s patent rights. The Plaintiffs do not manufacture or sell
directly laminate flooring products in Canada but they are present in the Canadian
market through importers of their licensed products.
[10]
The Defendant Triforest is a Canadian importer,
distributor and retailer of laminate flooring products. Triforest operates
three stores in Canada, one in Markham, Ontario and two in the Vancouver area
in British Columbia. It has a total of 20 employees. Triforest sells its
laminate flooring products to retailers in association
with at least the trademarks TOUCAN and TOUCAN FOREST PRODUCTS, and the
retailers in turn resell them to Canadian customers. The laminate flooring
products currently sold by Triforest are not licensed by the Plaintiffs [the
Unlicensed Products].
[11]
The three individual Defendants are all directors
of Triforest. They are members of the same family, Mr. Zhang and Ms. Feng being
husband and wife and Ms. Zhang being their daughter.
[12]
The Unlicensed Products imported by Triforest
are manufactured by at least two companies located in China, namely Chuzhou
Runlin Wood Industry Co Ltd [Runlin] and Shenglang Wood Co, Ltd [Shenglang].
Triforest, Runlin, Shenglang and the three individual Defendants are also associated
with a third Chinese company, Chuzhou Jiude Wood Co, Ltd [Jiude]. Shenglang was a licensee of the Unilin Group from January
2014 until March 2016, when its license was terminated due to Shenglang’s
inaccurate reporting of products manufactured and sold under license, and thus of
the royalties due to Unilin. Runlin and Jiude are not and have never been
licensees of Unilin. Mr. Zhang, Ms. Feng and Ms. Zhang,
are also the shareholders and legal representatives of the three Chinese
manufacturers Runlin, Shenglang and Jiude.
[13]
In other words, the three individual Defendants
are involved in both Triforest’s business activities in Canada and in the Chinese
companies that manufacture and export the Unlicensed Products imported and
distributed in Canada by Triforest.
[14]
The Defendant Molson sells laminate flooring
products imported into Canada by Triforest from two retail locations located in
Markham, Ontario and Mississauga, Ontario. According to the Plaintiffs’ investigation
of publicly available information data, Molson is estimated to be the largest Canadian
importer of unlicensed laminate flooring products manufactured by Runlin, after
Triforest.
B.
The Plaintiffs’ patents
[15]
Unilin owns a vast portfolio of patents and
patent applications around the world pertaining to the Glueless Locking
Technology, including Canadian Patent Nos. 2,475,076 [the 076 Patent] and
2,522,321 [the 321 Patent], directed at certain aspects of the Glueless Locking
Technology [collectively, the Canadian Patents]. FIL is a licensee of the Canadian
Patents, and has the right to grant sublicenses.
[16]
Over the years, the Unilin Group has developed
an extensive licensing program for the Glueless Locking Technology, whereby Unilin
grants licenses to manufacturers around the world to manufacture and sell
flooring products incorporating this technology. At present, the Unilin Group has
approximately 150 active licensees for the Glueless Locking Technology and, on
the basis of data available to the Plaintiffs, some 49 Canadian importers of
laminate flooring products have exclusively imported Unilin’s licensed products
in 2016.
[17]
In 2012, the Plaintiffs developed a program
pursuant to which licensed manufacturers in certain countries (including China)
must affix a holographic authentication label [the L2C Label] to each box of
flooring products they manufacture under license from the Plaintiffs [the L2C
Program]. The purpose of the L2C Program was to more easily identify Unilin’s licensed products in the marketplace and
more accurately trace the complete volume of products incorporating the
Glueless Locking Technology manufactured by its licensees.
[18]
The Unilin Group has distributed over 143
million L2C Labels to its licensees since the start of the L2C Program in April
2012. Since that time, these licensees have reported the manufacture and sale
of approximately 280 million square meters of laminate flooring products. In
addition, the Plaintiffs have spent time and resources enforcing their patents
related to the Glueless Locking Technology throughout the world, including in
Canada.
C.
History of the proceedings
[19]
Around August 2014, the Plaintiffs became aware
of Triforest’s alleged infringing activities. An investigation by the Plaintiffs
uncovered that Triforest imported, distributed and sold in Canada laminate
flooring products manufactured by Runlin that were not licensed by the
Plaintiffs, that allegedly infringe several claims of the Canadian Patents and
that did not bear the L2C Label.
[20]
Between September 2014 and September 2015, the
Plaintiffs and their counsel wrote several letters to Triforest requesting that
it cease importing and selling unlicensed laminate flooring. In October 2015,
representatives of Triforest (including Ms. Feng) met with counsel for the
Plaintiffs. The evidence submitted by the Plaintiffs shows that, during that
meeting, it was confirmed
that Triforest imported Unlicensed Products manufactured by Runlin. Ms. Feng also
represented that Triforest would not be in a position to compensate the
Plaintiffs for the unpaid royalties associated with the past importation and
sale of the Unlicensed Products and that if Triforest were forced to do so, it
would go bankrupt. Triforest also confirmed at the meeting that it would cease
selling unlicensed laminate flooring products in Canada.
[21]
In early 2016, the Plaintiffs learned that,
despite the October 2015 meeting, Triforest had continued to import into Canada
significant amounts of unlicensed laminate flooring products from Runlin. According to the Plaintiffs’ investigation, as of August 2016,
Triforest had imported close to one million square meters of unlicensed
laminate flooring products from Runlin to Canada.
[22]
Between October 2013 and April 2015, the
Plaintiffs also sent letters to Molson. At first, it was to inform Molson about
the L2C Program, the L2C Label and the patents held by the Unilin Group on
laminate flooring products incorporating the Glueless Locking Technology. When
they learned that Molson was selling laminate flooring products manufactured by
Runlin and supplied by Triforest, the Plaintiffs requested that Molson cease its
importation and sale of unlicensed laminate flooring products.
[23]
In May and June 2016, investigators were retained
by the Plaintiffs to purchase sample flooring products sold by Triforest and
Molson in Toronto and Vancouver. The vast majority of the boxes of Unlicensed
Products obtained by the investigators did not bear L2C Labels. In June and
July 2016, the Plaintiffs’ technical expert, Dr. Joseph Loferski, proceeded to
test and analyse some of the sample flooring products purchased by the
investigators, in order to assess whether they infringe any of certain specific
claims of the Canadian Patents. Dr. Loferski issued his opinion in October 2016 and concluded that each and every element of claims 13 to 17, 19, 20 and
21 of the 076 Patent and of claims 10, 11 and 12 of the 321 Patent were found
in each of the samples of the products he had analysed.
[24]
In October 2016, Mr. Olivier Soucisse, an
analyst investigator, was engaged by the Plaintiffs to investigate the
financial situation of the Triforest Defendants. Mr. Soucisse conducted background
checks, ascertained ownership of real estate and other assets, and gathered
wealth and financial information on these Defendants. Mr. Soucisse issued his
report in November 2016, indicating that the Canadian assets of the Triforest
Defendants included heavily leveraged real estate, as well as bank accounts for
which the details and contents were unknown.
[25]
On December 6, 2016, the Plaintiffs commenced an
action for infringement against the Defendants and brought an ex parte
motion for a Mareva injunction against the Triforest Defendants. On the basis
of the evidence then provided by the Plaintiffs, including affidavits from the
investigators, from Dr. Loferski, from Mr. Soucisse and from a representative
of FIL, Ms. Christine Walmsley-Scott, the ex parte motion was heard and
granted by this Court on December 19, 2016. The Mareva Injunction Order was directed
at Triforest, at the three individual Defendants and at various banks and
financial institutions.
D.
Settlement privilege issue
[26]
The Triforest Defendants claim that the
Plaintiffs improperly rely on certain documents which are the subject of
settlement privilege. These documents relate to the October 2015 meeting
between representatives of Triforest and counsel for the Plaintiffs, where the importation
of Unlicensed Products and the alleged infringement of the Plaintiffs’ Canadian
Patents were discussed.
[27]
I do not agree with the Triforest Defendants. It
is well established that the settlement privilege requires the presence of
three conditions: a litigious dispute in existence or within contemplation; a
communication made with the express or implied intention that it would not be
disclosed to the court in the event negotiations failed; and a communication
made with the purpose to attempt to effect a settlement (Kirkbi AG v Ritvik
Holdings Inc, [2002] FCJ No 793 at para 175). However, there is an
exception to the rule of settlement privilege where the communication subject
to privilege is not used as evidence of liability for the conduct which is the
subject of negotiations or of weak cause of action, but is used for other
purposes. In those circumstances, the privilege does not bar production in
Court (Sopinka, Lederman & Bryant, The Law of Evidence in Canada, 4th
ed, Markham: LexisNexis Canada Inc, at para 14.343; Sabre Inc v
International Air Transport Assn, [2009] OJ No 903 at paras 20-21).
[28]
This is the case here, as the Plaintiffs do not
rely on the impugned documents to establish the liability of the Triforest Defendants
for the alleged infringement of its Canadian Patents, but instead as evidence
that Triforest were aware of the Plaintiffs’ licenses and that its
representatives had then indicated that they would not have the financial
resources to pay the license fees on all the Unlicensed Products if they had
to.
[29]
These documents and the arguments relying on
their content can therefore be properly considered by this Court in the context
of the Plaintiffs’ Review Motion.
III.
Analysis
A.
Execution of the Mareva Injunction Order
[30]
The first question to be determined is whether
the Mareva Injunction Order issued on December 19, 2016 was lawfully executed.
[31]
The issue on this first portion of the motion
brought by the Plaintiffs is to review the execution of the Mareva Injunction
Order to determine if the execution was lawful and proper. This is not an
appeal on the merits of the Mareva Injunction Order granted or a motion for a
stay of the Order. Nor is it a motion to vary or set aside the Mareva
Injunction Order pursuant to Rule 399.
[32]
On the record before me, I am satisfied that, in
the circumstances of this case, the Mareva Injunction Order was lawfully
executed by the Plaintiffs.
(1)
Mareva injunctions
[33]
A Mareva injunction is a type of interlocutory
injunction whereby the assets of a party are frozen so that they cannot be
removed from the jurisdiction or dissipated in order to frustrate judgment. This
is an exceptional form of injunction, granted on the basis that there is a
genuine risk that the defendants will dissipate their assets or remove them
outside of the jurisdiction prior to judgment, which would render judgment
against that party useless, as there would be nothing against which to enforce it.
[34]
A Mareva injunction is a most extraordinary
remedy. The general rule established in Lister & Co v Stubbs,
[1886-90] All ER 797 (CA) is that execution cannot be obtained prior to
judgment and judgment cannot be obtained prior to trial (Aetna Financial
Services v Feigelman, [1985] 1 S.C.R. 2 [Aetna] at 10; Eli Lilly
Canada Inc v Novopharm Limited, 2010 FC 241 [Eli Lilly] at para 15).
The fundamental principle is that a litigant is not entitled to a remedy or
execution against a defendant’s assets before having established liability on
the part of that defendant. Moreover, the Mareva injunction is typically an ex
parte order, which puts an even higher threshold on the moving party. The granting
of a Mareva injunction is therefore only available where the strict conditions
for its issuance are met, and the courts should be prudent and cautious before
issuing one.
[35]
The test for the granting of a Mareva injunction
is well-established and was first developed by Lord Denning in Third
Chandris Shipping Corporation v Unimarine SA, [1979] 1 QB 645 (CA) [Third
Chandris]. The requirements outlined by Lord Denning in Third Chandris
have been cited with approval in Canada, and the Canadian courts have developed
and re-articulated them in various cases (Chitel et al v Rothbart et al
(1982), 141 DLR (3d) 268 (Ont CA) [Chitel] at paras 43-57; Aetna at
19-21; Marine Atlantic Inc v Blyth et al (1993), 113 DLR (4th)
501 (FCA) [Marine Atlantic] at paras 5-10; Eli Lilly at paras
17-20; Cho v Twin Cities Power-Canada, 2012 ABCA 47 at para 5).
[36]
Further to those precedents, the moving party must
therefore satisfy the following test to obtain a Mareva injunction:
A. establish a strong prima facie case;
B. meet the five following guidelines developed in Third Chandris
as modified and rephrased in Chitel:
i.
make full and frank disclosure of all matters in
its knowledge which are material for the judge to know;
ii.
give particulars of its claim against the
defendant, stating the ground of its claim and the amount thereof, and fairly
stating the points made against it by the defendant;
iii.
give some grounds for believing that the
defendant has assets in the jurisdiction;
iv.
give some grounds for believing that there is a
risk of the assets being removed from jurisdiction or dissipated in order to
frustrate judgment; and
v.
give an undertaking in damages in case it fails
in its claim or the injunction turns out to be unjustified; and
C.
satisfy the regular tripartite test for an
interlocutory injunction described in RJR-MacDonald, namely the presence
of a serious issue to be tried, irreparable harm if the injunction is not
granted and the balance of convenience favouring the moving party.
[37]
If the moving party fails on any of these
conditions, the courts should refuse the Mareva injunction.
(2)
Execution of the Mareva Injunction Order
[38]
The terms regarding the execution of the Mareva
Injunction Order were set out in the Order.
[39]
The Mareva Injunction Order required that the
Plaintiffs deposit with the Court the amount of $50,000 as security for damages
prior to service upon the Defendants, banks or financial institutions. The
Plaintiffs did file the $50,000 deposit with the Court on December 20, 2016.
[40]
The Mareva Injunction Order was then sent by
facsimile and formally served on December 21 and 22, 2016 on eight banks
and financial institutions (namely Bank of Montreal, CIBC, HSBC, Royal Bank of
Canada, Scotiabank, TD Canada Trust [TD], Bank of China and Industrial and
Commercial Bank of China [ICBC]). The Mareva Injunction Order was accompanied
by a letter from counsel for the Plaintiffs, indicating what the Mareva
Injunction Order required these banks and financial institutions to accomplish.
The letter notably mentioned to the banks and financial institutions that the
Order was to prevent the Triforest Defendants from transferring assets
(including by the payment of monies) outside of Canada.
[41]
The Mareva Injunction Order was then properly served
upon Triforest, Ms. Feng and Ms. Zhang on December 21, 2016, and the
following day upon Mr. Zhang and Molson. The affidavits filed by the Plaintiffs
in support of the Review Motion attest to that.
[42]
As required, the Plaintiffs brought their motion
to review the execution of the Mareva Injunction Order before the Court within 14
days of service upon all Defendants, namely on January 4, 2016, one day before
the scheduled expiry of the Order. Plaintiffs’ counsel also filed with the
Court the written reports received from the banks and financial institutions
further to the execution of the Order. There is no indication that the Plaintiffs
did not compensate the banks and financial institutions for reasonable expenses
they incurred in carrying the searches and freezing of assets ordered.
[43]
Based on my review of the evidence, I find that
the procedure followed was in accordance with the terms of the Mareva
Injunction Order, that no improper execution of the Order arose and that the
behaviour of the Plaintiffs and their counsel involved with the execution of
the Order was irreproachable. I also do not find that the Order was obtained
for an improper purpose and I observe that, at the time the Order was issued,
the conditions for the issuance of the ex parte Mareva injunction were
met to the satisfaction of the presiding judge.
[44]
The Triforest Defendants claim that the Mareva
Injunction Order cannot be considered as having been lawfully executed on two
grounds: they contend that the Plaintiffs have failed to make a full and frank
disclosure, and they complain about the fact that the banks and the financial
institutions ended up freezing all banking accounts of the Triforest
Defendants, thereby widely exceeding the scope of the Order.
[45]
I am not convinced that these arguments raised
by the Triforest Defendants reflect an unlawful execution of the Mareva
Injunction Order.
[46]
I agree that a party seeking an ex parte
Mareva injunction is required to make full and frank disclosure of all material
facts as the Court is asked to grant such order solely on the basis of the
evidence presented by the moving party. It is indeed a well-established
principle of our law that a party seeking the extraordinary relief of an ex
parte injunction must provide a balanced and complete presentation of the
facts. A fact may be material even if it is not determinative. However, I do
not find that there was a lack of full and frank disclosure in the Plaintiffs’
application for the Mareva Injunction Order or that they omitted or
misrepresented material facts. On the contrary, I conclude that the Plaintiffs
lived up to their obligations and duties imposed by the law.
[47]
The Triforest Defendants essentially take
exception with the Plaintiffs’ reliance on the fact that they had been recently
unable to pursue a similar claim for infringement against a third party, MGA
Commodities Inc. [MGA], who became insolvent before the Plaintiffs could
execute a judgment against it. In their submissions, the Plaintiffs expressed
strong concerns that the Triforest Defendants would imitate MGA and seek
bankruptcy protection to avoid paying any amount for which they would be liable
to the Plaintiffs for patent infringement. The Triforest Defendants claim that the Plaintiffs failed to disclose to the Court that there
was no relationship between MGA and Triforest; that by November 2016, the
financial investigations into the Triforest Defendants showed significant
assets in Canada and no risk of insolvency; and that the MGA case dealt with
counterfeiting of the Plaintiffs’ laminate flooring products as well as
allegations of copyright and trademark infringement, unlike the present
proceeding limited to an alleged patent infringement.
[48]
I am satisfied that the Plaintiffs made a full
and frank disclosure of the MGA situation in their attempt to draw a parallel
between that case and the current case. At no point did the Plaintiffs claim or
suggest that there was a relationship between MGA and the Triforest Defendants.
In addition, the results of the Plaintiffs’ financial investigations, the
existence of the real estate assets owned by the three individual Defendants and
the financial situation of all Triforest Defendants were fully disclosed
through the affidavit of Mr. Soucisse. Finally, the failure to specifically
mention the counterfeiting aspect of the MGA case was not, in my opinion, a material
element. In fact, Ms. Walmsley-Scott testified that, in her view, infringement
and counterfeiting were serious problems of a similar nature for the Unilin
Group. Moreover, the parallel drawn with the MGA situation was made with
respect to the inability to collect payment following an infringer’s insolvency
rather than in relation to the features and extent of the infringement by MGA.
[49]
The Triforest Defendants also complain about the
fact that the Plaintiffs have been unable to properly enforce the Mareva
Injunction Order, which only permitted the prohibition of money transfers by the
Triforest Defendants to recipients outside of Canada. Instead, the banks and
financial institutions have completely frozen the bank accounts and credit
cards of the Triforest Defendants, preventing them from depositing or withdrawing
any funds in the normal course of their livelihoods or business.
[50]
The Plaintiffs acknowledge that the financial assets
of the Triforest Defendants have been completely frozen, that this was not the
remedy contemplated by the Mareva Injunction Order, and that this went beyond
the scope of the terms of the Mareva Injunction Order. The banks and financial
institutions that were served with the Mareva Injunction Order indicated to
Plaintiffs’ counsel that it was not possible for them to limit their
application of the Mareva Injunction Order to its scope as issued. The evidence
before me and the representations made by counsel at the hearing, however,
indicate that, as soon as this became known to the Plaintiffs, their counsel had
discussions with the banks and the financial institutions to find a solution,
which proved difficult to do during the Christmas holiday period.
[51]
While this might have raised an issue with respect
to the enforceability of the Mareva Injunction Order and might have provided
grounds to the Triforest Defendants to vary the Order or to set it aside, I am
not ready to find that this constitutes an unlawful or improper execution of
the Order by the Plaintiffs or its representatives. I note that, in the interim
order issued with the consent of the Triforest Defendants on January 5, 2017, to
remain valid until the issuance of this judgment, the terms that the banks and
financial institutions had found impossible to implement have been modified and
that the banking accounts of the Triforest Defendants are no longer frozen.
(3)
Conclusion on the review of the Order
[52]
For the above reasons, I am thus of the view
that the execution of the Mareva Injunction Order was carried out lawfully by
the Plaintiffs. The Plaintiffs are therefore authorized to withdraw the deposit
of $50,000 they had filed with the Court on December 20, 2016.
B.
Interlocutory Mareva injunction
[53]
The second issue to be determined is whether the
Mareva Injunction Order should be converted into an interlocutory Mareva injunction
order. To succeed, the Plaintiffs have to demonstrate that all the components of
the test for the issuance of Mareva injunctions remain satisfied further to the
evidence obtained from the execution of the Mareva Injunction Order and the
receipt of the response materials filed by the Triforest Defendants.
[54]
I have reviewed the voluminous evidence obtained
by the Plaintiffs from the four banks and financial institutions that provided
banking accounts information on the Triforest Defendants, as well as the
evidence tendered by the Triforest Defendants through the affidavits of Mr.
Steve Wang, accountant for Triforest, and Ms. Zhang. The Plaintiffs’ evidence
is contained in the various affidavits of Ms. Julie Morin and of Ms. Van Khai
Luong containing the letters and reports from the banks and financial
institutions, and in the extracts of the Triforest Defendants’ bank statements
and passports prepared by Plaintiffs’ counsel for the hearing before this Court.
On the evidentiary record before me, I am not satisfied that there is clear and
convincing evidence allowing me to conclude that a remedy as exceptional and
extraordinary as an interlocutory Mareva injunction should be issued in this
case. More specifically, I do not find that there is evidence supporting, on a
balance of probabilities, a real risk that the Triforest Defendants would
remove their assets from Canada or dissipate them outside of normal and lawful
course of business, for the purpose of avoiding or rendering ineffective a judgment
that the Plaintiffs may obtain on their claim of infringement. The evidence
uncovered through the execution of the Mareva Injunction Order simply does not
confirm the risk anticipated and feared by the Plaintiffs when the ex parte
Order was issued.
[55]
This “genuine risk”
factor contained in the five Third Chandris / Chitel guidelines is the “overriding consideration” for the issuance of a
Mareva injunction (Aetna at 24), and I conclude that the Plaintiffs do
not satisfy it. As this is sufficient to refuse the interlocutory Mareva
injunction, there is no need to consider the other factors and conditions
prescribed by the jurisprudence on Mareva injunctions.
(1)
Strong prima facie case
[56]
That said, since the parties and their
respective counsel spent a fair portion of their written and oral submissions
on the issue of the “strong prima facie case”
of infringement, and in anticipation of the discussion below on the RJR-MacDonald
test, I will make the following remarks on this point.
[57]
The Triforest Defendants dispute the assertion
that the Plaintiffs have a strong prima facie case against them. They
raise four arguments in support of their position. The Triforest Defendants first
assert that the infringement analysis of Dr. Loferski is flawed because he did
not measure the density of the core in the Unlicensed Products, whereas claims
in each of the 076 Patent and the 321 Patent require that the product be made
with HDF or MDF. The Triforest Defendants also contend that claim 10 of the 321
Patent requires “elastic deformation of the groove”
and that Dr. Loferski admitted that the lower lip of the Triforest products
deformed, not the groove. They further submit that the 076 Patent and the 321
Patent are invalid on the basis of various grounds including overbreadth, claim
ambiguity, indefiniteness, anticipation by other patents and lack of utility.
Finally, the Triforest Defendants have provided decisions issued in other
countries where Unilin Group’s patents apparently corresponding to the Canadian
Patents have been found invalid, and where the corresponding European patents
had their claims narrowed.
[58]
For the following reasons, I am not satisfied
that the Triforest Defendants have provided clear and convincing evidence
disputing the validity of the 076 Patent and the 321 Patent, to the point where
the statutory presumption of validity has been displaced and where the
Plaintiffs’ case no longer falls within the range of a strong prima facie
case of infringement. The Triforest Defendants may have laid the ground for
some arguable points on the merits of the Plaintiffs’ case of patent
infringement, a matter to be decided at trial. However, at this stage, I find that
the evidence adduced by the Plaintiffs provides answers to the various arguments
raised by the Triforest Defendants against the validity of the Canadian Patents,
sufficient to satisfy me that the Plaintiffs have demonstrated a strong prima
facie case.
[59]
I pause to note that counsel for the Triforest
Defendants opposes the production of the second supplemental affidavit of Ms. Luong
filed on behalf of the Plaintiffs, which contains responding evidence on the
issue of prior art documents submitted to the Canadian Patent Office in 2006,
during the prosecution of the Canadian Patents. I do not agree. I am instead
satisfied that this affidavit can be admitted as it is relevant and is
assisting the Court on an issue raised by the Triforest Defendants in their response
and discussed at length in the cross-examination of Ms. Walmsley-Scott. I am
also of the view that it causes no undue prejudice to the Triforest Defendants
and that it serves the interests of justice to have it on the record (Atlantic
Engraving Ltd v Lapointe Rosenstein (2002), 23 CPR (4th) 5 (FCA)
at paras 8-9).
[60]
Turning to the Triforest Defendants’ arguments, I
am not persuaded that the cross-examination of Dr. Loferski allows to conclude
that, since the density of the core in Triforest’s Unlicensed Products was not
measured, it was not possible for Dr. Loferski to conclude that these products
infringed the identified claims of the Canadian Patents. Dr. Loferski stated in
his evidence that he was able to confirm that the Triforest Unlicensed Products
were made of HDF and MDF, and there is evidence showing that Triforest
explicitly advertises that its products are made of HDF. Similarly, on the
elastic deformation of the groove, I agree with the Plaintiffs that there is
evidence showing that Dr. Loferski equates the groove with the lower lip.
[61]
As to the decisions arising from the other
jurisdictions, I am not persuaded that they erode the strong prima facie
case of the Plaintiffs. Despite certain challenges in Europe, the Plaintiffs’
patents have remained valid and have been slightly modified further to those
decisions, prior to the Canadian Patents being issued. These decisions, in my
view, are not sufficient to question the validity of the Canadian Patents.
Patent law varies between jurisdictions and the scope of the claims and of the
monopolies granted to the Plaintiffs’ various patents related to the Glueless
Locking Technology will therefore differ from one country to the other. Absent
any expert evidence challenging the validity of the Canadian Patents, I do not
find that the decisions issued in the UK, France and the Netherlands pertaining
to patents owned by the Unilin Group in these jurisdictions, as well as the two
pieces of prior art cited by the Triforest Defendants, are sufficient to
dispute, cast doubt or challenge the deemed validity of the Plaintiffs’
Canadian Patents.
[62]
More specifically, the evidence shows that the
relevant UK patent was declared valid following an amendment, and a
corresponding European patent was also found valid following opposition
proceedings. Similarly, in France, there was consent to the reversal of the
French decision invalidating certain claims of a European patent, following a parallel
opposition to the same patent decided in the Plaintiffs’ favour after the
issuance of the French decision. As to the decision in the Netherlands, I agree
with the Plaintiffs that it is of no relevance, as it pertains to a patent directed
at an invention different from the inventions covered by the Canadian Patents. Finally,
the Plaintiffs point out that the pieces of prior art raised by the Triforest Defendants
were submitted and considered by the Canadian patent authorities prior to the
issuance of the Canadian Patents.
[63]
I am therefore of the view that the Plaintiffs have demonstrated a strong prima facie
case of infringement against the Triforest Defendants. A strong prima facie
case requires more than an arguable case; it implies that the moving party has
a high chance of success on the merits. In this case, the Plaintiffs own the
rights in the 076 and 321 Patents, including the exclusive right, privilege and
liberty of making, constructing, using and selling to others to be used, the
inventions as claimed therein. This was confirmed in the affidavits of Ms.
Walmsley-Scott and Dr. Loferski. There is an initial presumption of validity. The
Canadian Patents are in force since 1997, and their validity has never been
challenged in Canada. Furthermore, the expert evidence of Dr. Loferski demonstrates
that the Unlicensed Products imported and sold by the Triforest Defendants incorporate
all of the elements of many claims of the 076 Patent and 321 Patent and infringe
upon the Plaintiffs’ exclusive patent rights. The evidentiary record also satisfies
me that the Triforest Defendants sell and distribute Unlicensed Products that may
infringe upon the 076 and 321 Patents and do not bear any L2C Label. The
Plaintiffs’ investigations further show that the Defendants hold a significant inventory
of Unlicensed Products. All of this evidence points to a high chance of success
for the Plaintiffs in their action for infringement.
[64]
The Triforest Defendants claim that statutory
presumption alone is not sufficient to establish a prima facie case
required to support an interlocutory injunction when affidavit evidence is
offered disputing the validity of the patent,
relying on Teledyne Industries Inc et al v Lido Industrial Products Ltd (1977),
33 CPR (2d) 270 at 276 [Teledyne]. However, Teledyne was a case
where expert affidavit evidence from a patent agent had been offered to dispute
the validity and infringement of the patent. In addition, this was a case where
the patent was of recent origin and its validity had never been established.
This is not the situation here. On the contrary, the Triforest Defendants did
not submit any expert affidavit evidence challenging the validity of the
Plaintiffs’ Canadian Patents.
[65]
Accordingly, I am satisfied that the Plaintiffs
have made out a strong prima facie case of patent infringement against
all Defendants.
(2)
Real risks of removal or dissipation of assets
[66]
The problem with the Plaintiffs’ motion for an
interlocutory Mareva injunction is the requirement of a real risk of removal or
dissipation of assets by the Triforest Defendants.
[67]
The Plaintiffs claim that the banking
information received further to the execution of the Mareva Injunction Order confirms
that the Triforest Defendants have liquid assets in Canada, and that they
frequently and easily transfer large sums of money in and out of their Canadian
bank accounts, to and from unknown destinations. On the basis of these banking
patterns and of the Triforest Defendants’ commercial activities in China, the
Plaintiffs submit that there is no question that the conversion of the Mareva
Injunction Order into an interlocutory Mareva injunction order is necessary to
ensure that any final judgment of this Court will be effective and enforceable.
[68]
I disagree. Despite the able representations made
by counsel for the Plaintiffs, I am not persuaded that, with the evidence
uncovered by the Plaintiffs and the evidence filed by the Triforest Defendants
on this Review Motion, the demanding test for the issuance of an interlocutory Mareva
injunction is now met.
(a)
The Chitel test
[69]
True, the real risk of assets being removed from
the jurisdiction or dissipated by the defendant to avoid the possibility of
judgment is only one of the five Third Chandris / Chitel factors and it
may be that the Plaintiffs satisfy many of the other conditions. However, this “genuine risk” factor is the overriding consideration
for granting a Mareva injunction (Aetna at 24). Evidence of a threat to
arrange assets to as to defeat judgment and “for the
purpose of avoiding judgment” is key (Marine Atlantic at para 9).
[70]
On this point, it is worth citing the exact test
I must apply, as set out in Chitel at para 57. It reads as follows:
The applicant must persuade the Court by his
material that the defendant is removing or there is a real risk that he is
about to remove his assets from the jurisdiction to avoid the possibility of a
judgment, or that the defendant is otherwise dissipating or disposing of his
assets, in a manner clearly distinct from his usual or ordinary course of
business or living, so as to render the possibility of future tracing of assets
remote, if not impossible in fact or in law.
[71]
The Plaintiffs therefore had to provide clear
and convincing evidence that, on a balance of probabilities, 1) the Triforest Defendants
are removing or there is a real risk that they are about to remove their assets
from Canada or are otherwise dissipating or disposing of their assets, 2) they
do this in a manner clearly distinct from their usual or ordinary course of
business or living, 3) so as to render the possibility of future tracing of the
assets remote, if not impossible, or for the purpose of avoiding the
possibility of judgment.
[72]
The burden is on the moving party to prove each
of those three elements. Only where all those criteria are met can a Mareva
injunction prevent the impugned behaviour. It would therefore not be enough to
provide evidence that the defendant is having financial difficulties or that
the defendant will probably remove its assets from the jurisdiction, if there
is no evidence to suggest that the defendant also has a purpose to defeat or
frustrate a potential judgment. If the assets are not dissipated for the
purpose to avoid judgment, or if transfers are carried out in the normal course
of a defendant’s affairs, then the moving party, like all others with claims
against the defendant, must run the risk that the defendant may dissipate its
assets or consume them in discharging other liabilities and so leave nothing
with which to satisfy a judgment.
[73]
I pause to underline that, as the Supreme Court stated
in FH v McDougall, 2008 SCC
53 [McDougall], there is only one standard of proof in civil cases in
Canada, and that is proof on a balance of probabilities (McDougall at
para 46). In that decision, Mr. Justice Rothstein, for a unanimous court, said
that “it is inappropriate to
say that there are legally recognized different levels of scrutiny of the
evidence depending upon the seriousness of the case” and that the only legal rule in all cases is that “evidence must be scrutinized with care by the trial judge”
to determine whether it is more likely than not that an alleged event occurred
or is likely to occur (McDougall at para 45). Evidence “must always be sufficiently clear, convincing and cogent to
satisfy the balance of probabilities test” (McDougall at para 46). This, evidently, applies to
the type of evidence needed for a Mareva injunction.
[74]
I agree with the Plaintiffs that, in determining
whether there is a genuine risk that a defendant removes its assets from Canada
or dissipates them, the courts must consider all of the relevant circumstances,
including the nature of the conduct alleged and the type of assets involved (Caisse
populaire Laurier d'Ottawa Ltee v Guertin, [1983] OJ No 2221 (Ont HC) [Laurier]
at para 17; Insurance Corp. of British Columbia v Patko, 2008 BCCA 65 at
para 29). But in the end, what needs to be assessed is “whether
in all of those circumstances the assets will be dealt with in a manner that
will serve to hamper or defeat the plaintiff’s attempts to realize on any judgment
they might obtain” (Laurier at para 17).
[75]
A motion like this one ultimately turns on its
facts. And, when all of the circumstances are considered, the evidence adduced in
this case fails to convince me that, on a balance of probabilities, the three components
of the test set out in Chitel are met. What the Plaintiffs more
specifically overlooked here are two fundamental elements of the test: acting
out of the ordinary course of business, and a purpose or intent to evade
legitimate execution and enforcement of a potential adverse decision.
(b)
The evidence
[76]
I find that the evidence on the record before me
shows that:
A. Neither Triforest nor the three individual Defendants are currently insolvent
or face financial difficulties;
B. The Triforest Defendants own [REDACTED] real estate assets in
Canada, [REDACTED];
C. Before the expiration of the Mareva Injunction Order on January 5,
2016, four financial institutions confirmed that they did not locate any
account in the name of the Triforest Defendants. Counsel for the Plaintiffs
however received information and transaction history pertaining to certain banking
accounts that the Triforest Defendants hold [REDACTED];
D. The deposit and withdrawal patterns in the various banking accounts of
the Triforest Defendants date back to 2013 and 2104 (and sometimes to 2011 and
2012) for the majority of their banking accounts;
E. The majority of the evidence singled out by the Plaintiffs in their extracts
provided to the Court relate to 2012, 2013, 2014 and 2015. More limited
evidence has been provided for 2016;
F. The travel evidence regarding the three individual Defendants, adduced
to reflect the correlation between banking withdrawals and travel abroad to
China, essentially date back to 2012 and 2014, with only one single instance in
2016;
G. The banking accounts of the Triforest Defendants generally contain
vague and general entries [REDACTED], not allowing to know the source or the destination
of the money transfers;
H. The [REDACTED] banking accounts report regular transfers to [REDACTED] institutions offering various cross-border
financial services including global payments solutions, foreign exchange and
international transfers;
I.
The evidence does not allow to confirm or
corroborate whether the transfers of money [REDACTED], are transfers out of the
jurisdiction;
J. The payments made to the supplier Runlin were well identified in one
[REDACTED] banking account, but these explicit entries were only for one
supplier and were limited to a few payments made in the first quarter of 2016;
K. Several banking accounts of Triforest and of the three individual
Defendants [REDACTED] showed substantial balances in December 2016, at the time
the accounts were frozen further to the Mareva Injunction Order. [REDACTED];
L. Ms. Feng has a banking account [REDACTED] showing no movement since
January 2015;
M. The various [REDACTED] banking accounts of Triforest show lots of deposits
and withdrawal activities, with significant balances regularly remaining in the
accounts throughout the period for which the accounts have been provided.
[77]
As was the case in Eli Lilly, I am of the
view that, when considered in its totality, this evidence does not establish,
on a balance of probabilities, that the Triforest Defendants are about to
remove assets from Canada or that in making their various money transfers, they
are acting in anything other than the ordinary and usual course of their business
and livelihood. Further, there is insufficient evidence on the record to prove,
on a balance of probabilities, that the Triforest Defendants are transferring
these amounts for the purpose of avoiding judgment or that they would wind up
their Canadian operations rather than pay a judgment awarded to the Plaintiffs.
(c)
No expatriation or dissipation of assets
[78]
On the removal of assets out of the jurisdiction
or the dissipation of assets, I find no clear and convincing evidence able to support
the affirmations made by the Plaintiffs. At best, the evidence is inconclusive
and speculative. To use the words of Ms. Walmsley-Scott in her
cross-examination, there is a belief “that because of
the defendants’ close ties to China that there’s a significant risk that they could
transfer all their assets out of Canada” (my emphasis). This is too
speculative and insufficient to constitute evidence of expatriation of assets on
which to base the grant of a Mareva injunction, as the removal of assets must
be more than a mere possibility.
[79]
I am also not persuaded, based on the record
before me, that I can reasonably infer from the evidence on the transfers [REDACTED],
that this is to be read as necessarily meaning transfers outside of Canada, in
the absence of other corroborating evidence. I am also not ready to infer that regular
[REDACTED] from a banking account, without any
more detail and without any other evidence, is sufficient to demonstrate, on a
balance of probabilities, the existence of a transfer outside the jurisdiction
or a dissipation of assets. Stated otherwise, I cannot conclude that it is more
likely than not that the required expatriation or dissipation of assets occurred
or is likely to occur.
[80]
True, the transaction history of the Triforest
Defendants’ [REDACTED] banking accounts shows that the accounts are sometimes kept
at a relatively low ongoing balance, that the Triforest Defendants frequently
deposit large sums of money in their accounts, and subsequently transfer
equally large sums of money out of the accounts a few days or weeks after the
deposits, normally by way of withdrawal or Internet transfer. But the evidence
also shows that substantial balances regularly remain in the Triforest
accounts. Further, as acknowledged by the Plaintiffs in two paragraphs in their
written submissions, the large deposits, withdrawals and transfers are more
often than not “to and from unknown destinations”.
[81]
I accept that the evidence on the banking accounts
of the Triforest Defendants reflects the transfer of significant withdrawals
and deposits representing a large amount of money in the past few years. I
understand that this may be a source of concern for the Plaintiffs. However, I
do not agree that this amounts to evidence of a genuine risk of removal of assets
out of Canada or of dissipation of assets.
(d)
Transfers in the usual course of business or
living
[82]
Turning to the second element of the Chitel
test, which is the disposition of assets in a manner clearly distinct from the
defendant’s usual or ordinary course of business or living, the reports of the
Triforest Defendants’ banking accounts provided [REDACTED] show large deposits,
withdrawals and transfers that have been going on for years, that clearly started
prior to the events leading to the Plaintiffs’ motion, and that do not exhibit
a change in behavior as a result of the Plaintiffs’ correspondences, meeting
with the Plaintiffs’ counsel in October 2015, or the commencement of their
action for infringement. The [REDACTED] bank records, in particular, show a
pattern of large transfers in and out of the Triforest Defendants’ banking
accounts that pre-date the events in question. This evidence does not support a
conclusion that these are or were transfers occurring outside of the normal
course of the livelihoods and business of the Triforest Defendants, and
actually supports the opposite conclusion. There is also no evidence suggesting
that this course of action is fraudulent or illegal.
[83]
Of course, given the vertical integration of the
Triforest Defendants’ operations, it is reasonable to infer that some of those
transfers and withdrawals made in the normal course of business must have
included money transfers to China, to the related manufacturers and suppliers of
laminate flooring products, or to the three individual Defendants. Since only a
few transactions with suppliers were clearly identified as such in the [REDACTED]
account, it is also reasonable to infer that [REDACTED] included payments to
suppliers. However, there is no evidence allowing me to conclude that these
money transfers are clearly distinct from the normal course of business or
living of the Triforest Defendants.
[84]
The banking accounts evidence obtained by the Plaintiffs
is voluminous. The problem for the Plaintiffs is that this evidence goes back
to 2012, 2013 and 2014 (and sometimes to 2011), and shows a recurring pattern
of deposits, withdrawals and transfers that have been occurring for years in
the banking accounts of the Triforest Defendants. There is no evidence reflecting
a change in the circumstances of the Triforest Defendants’ livelihood, business
or operations, or any risk of the Triforest Defendants removing assets out of
the usual or ordinary course of their livelihood or business in order to defeat
or frustrate an eventual judgment.
[85]
In her affidavit, Ms. Zhang also indicated that,
for the three individual Defendants, the source of the large deposits were from
accounts in China, line of credit accounts with the [REDACTED], Internet
transfers from other banks accounts held by them, or loan repayments by
Triforest. She stated that the large withdrawals were used for the purchase of
real estate, home renovations and transfers to other bank accounts held by the individual
Defendants, loans to Triforest, mortgage payments, tuition and living expenses.
Turning to Mr. Wang, he has affirmed in his affidavit that Triforest regularly
transfers funds from its [REDACTED] banking accounts to entities or persons
located in or outside of Canada for the purpose of fulfilling its payment
obligations for the normal operation of the business, including several
reoccurring monthly expenses such as payroll, payments to suppliers, rental
expenses and GST remittances. He testified that transfers made by Triforest
from its [REDACTED] banking accounts to entities or persons located in China
have been only for business-related purposes. This evidence of Ms. Zhang and of
Mr. Wang was not challenged nor contradicted.
[86]
On the evidentiary record before me, I therefore
find that the Triforest Defendants have not changed, and do not intend to
change, their usual methods of transferring their monetary assets and of running
their business. I note that their laminate flooring business is active and
continuing, both as manufacturers in China and importers in Canada, and that
Triforest has become one of the five largest importers of laminate flooring
products in Canada.
(e)
No purpose of avoiding judgment
[87]
Finally, turning to the third and last part of
the Chitel test, I can only consider granting a Mareva injunction if I can
conclude that the purpose and intention of the Triforest Defendants is to
defeat any judgment that the Plaintiffs may obtain against them. Again, there
is no clear and convincing evidence demonstrating, on a balance of
probabilities, that the purpose of the Triforest Defendants withdrawing the
funds from their accounts is not a legitimate one. The fact that these
transfers might affect the Plaintiffs’ ability to recover on any judgment it
may obtain does not, in and of itself, justify the granting of a Mareva
injunction.
[88]
As was the case in Aetna, there is no
evidence allowing me to find an improper motive behind the transfers of money
by the Triforest Defendants. The evidence instead shows that the transfers
reflect the history of conduct of the business and personal affairs carried out
by the Triforest Defendants, and there is no sufficient basis to find a purpose
on the part of the Triforest Defendants to default on their obligations, either
generally or to the Plaintiffs, if such an obligation is found to exist on the
merits (Aetna at 36).
[89]
In light of the evidence before me, I do not
find that, on a balance of probabilities, there is an improper purpose on the
part of the Triforest Defendants in the various transfers of funds observed in
their banking accounts. Nor am I persuaded that, on a balance of probabilities,
the evidence unearthed with the benefit of the Mareva Injunction Order support
a conclusion that there is a real risk that the Triforest Defendants will deal
with their banking accounts in a manner that will interfere with or defeat the Plaintiffs’
attempt to realize on any judgment they might obtain on the merits. I further
observe that the Plaintiffs’ investigation into the current status of the Triforest
Defendants’ finances showed no evidence of an intention by the Triforest
Defendants to defeat or frustrate an eventual judgment. It instead showed that
the bank accounts, loans, mortgages, credit cards and leases of the Triforest
Defendants were in good standing, and there was no evidence of dissipation of
assets, bankruptcy, collections or judgment against them. Their respective
financial situation is sound.
[90]
In any event, I note that evidence that a
defendant is insolvent or having financial difficulties, or the possibility
that potential judgment debtors may be declared bankrupt, is not sufficient to
justify a Mareva injunction (Marine Atlantic at para 9). There must be evidence
that the disposal of assets is “for the purpose of
avoiding judgment”: “[t]he removal of assets
from the jurisdiction by a resident defendant in the normal course of its
business, without there being any suggestion of an intent to defeat or
frustrate any eventual judgment recovery by the plaintiff, is not enough to
support a Mareva injunction” (Marine Atlantic at para 9).
[91]
I accept that representatives of Triforest have at
least been evasive if not untruthful with Plaintiffs’ counsel in October 2015,
that they have tried to hide the fact that they knew the source of Triforest’s Unlicensed
Products, and that they then indicated they would go bankrupt if they had to
pay royalties to the Plaintiffs for all their past importations of Unlicensed
Products. For the Plaintiffs, the October 2015 report from their counsel on the
meeting with Triforest is a key document. I acknowledge that, on the basis of
this document, there may have been some dishonesty on the part of the Triforest
Defendants at the time. However, considering all the circumstances and all the
evidence before me, I do not find that this October 2015 statement is enough to
tip the balance in favour of the Plaintiffs on the interlocutory Mareva
injunction, and to conclude that the transfers of money the Triforest
Defendants have been doing for years are for the purpose of avoiding judgment.
[92]
Looking at the matter with the added benefit of
the results from the execution of the Mareva Injunction Order, it is my view
that the significance of the October 2015 statement has atrophied with the
passage of time and with the dissonance observed between its contents and the more
recent evidence on the sound financial situation of the Triforest Defendants.
[93]
One other point is worth mentioning. The
evidence shows that the Triforest Defendants have ties to Canada. The three
individual Defendants became permanent Canadian residents in March 2012, have
lived in Canada since then, and own real estate assets in the country, [REDACTED].
Triforest operates three stores in Canada with 20 employees. Triforest has an
on-going business as one the five largest imports of laminate flooring products
in Canada, perhaps, I acknowledge, due to the benefit of Unlicensed Products
that could be infringing on the Canadian Patents of the Plaintiffs. This is not
reflective of a situation where defendants are about to flee the jurisdiction
or dissipate assets in order to avoid a judgment against them.
[94]
In other words, when all the evidence on the
record is considered, I am not persuaded that it is now sufficient to meet the third
dimension of the Chitel test and to support the issuance of the
interlocutory Mareva injunction now sought by the Plaintiffs. The evidence
uncovered through the execution of the Mareva Injunction Order does not confirm
the significance of the risk identified to obtain the initial Order.
(3)
Conclusion on the interlocutory Mareva
injunction
[95]
For the above reasons, I am unable to conclude,
based on all the circumstances of this case and on a balance of probabilities,
that there is real risk of removal of assets from the jurisdiction before a
judgment could be obtained by the Plaintiffs, or that assets would be
dissipated by the Triforest Defendants so as to frustrate a judgment, outside
of their normal course of business and operations. The evidence does not show
that, and it does not allow me to draw such inference. Evidence that the
Triforest Defendants regularly transfer large sums of money in and out of their
Canadian bank accounts, to and from unknown destinations, is not enough to
satisfy the stringent test established for Mareva injunctions, and to convince
me that the conversion of the Mareva Injunction Order into an interlocutory
Mareva injunction order is necessary to ensure that any final judgment of this
Court will be effective and enforceable.
[96]
I observe that, in its submissions to the Court,
Triforest is prepared to undertake to produce to the Plaintiffs an accounting
of past sales of its laminate flooring products in Canada for the period
starting on June 1, 2014, ending on the day before the date of signing such undertaking,
and to keep an accounting of current and future sales of its laminate flooring
products in Canada until the disposition of this matter or until the term of
the Canadian Patents, whichever comes first. I am of the view that it would be
in the interests of justice to keep that undertaking in place and that an order
to that effect seems just and appropriate in the circumstances.
C.
Interlocutory injunction
[97]
The third issue to be determined on this Review
Motion is whether an interlocutory injunction order should be issued against
all Defendants to prevent them from continuing to manufacture, use, sell or
import into Canada their unlicensed laminate flooring products until the
matters raised by the action for patent infringement are finally determined by
the Court. To succeed, the Plaintiffs have to demonstrate that each element of
the RJR-MacDonald test for the issuance of interlocutory injunctions is
met.
[98]
For the reasons that follow, I am not persuaded
that, on the record before me, the Plaintiffs have provided the required clear
and non-speculative evidence to demonstrate, on a balance of probabilities,
that they will suffer irreparable harm if the interlocutory injunction sought is
not granted.
(1)
The RJR-MacDonald test
[99]
It is trite law that for an interlocutory
injunction to be granted, the moving party must satisfy the three conditions set
out in RJR-MacDonald. In that decision, the Supreme Court held that, to
issue an order for injunctive relief, a court must first be satisfied that
there is a serious issue to be tried. Second, it must determine that the
applicant would suffer irreparable harm if the injunction were refused. Third, it
must find that the “balance of convenience”,
which contemplates an assessment of which of the parties would suffer greater
harm from the granting or refusal of the remedy pending a decision on the
merits, favours the moving party (RJR-MacDonald at 334). The tripartite test
is conjunctive, so all three elements have to be met in order for an injunction
to be granted.
[100] In recent decisions issued in the context of stays, as opposed to
interlocutory injunctions, the Federal Court of Appeal has indeed frequently
reminded that all three elements of the tripartite test have to be satisfied.
Finding the existence of a serious issue does not automatically bring with it
that the other two prongs of the tripartite test are satisfied. As the Federal
Court of Appeal stated in Janssen
Inc v Abbvie Corporation, 2014
FCA 112 [Janssen], each branch of the test adds something important and “none of the branches can be seen as an
optional extra” (Janssen
at para 19).
[101] I add that the Federal Court of Appeal has repeatedly considered
that the applicable test for interlocutory injunctions is the same as the test governing
the granting of stays of proceedings or of appeals (Toronto Real Estate
Board v Commissioner of Competition, 2016 FCA 204 at para 11; Janssen
at paras 12-17; Glooscap Heritage Society v Canada (National Revenue),
2012 FCA 255 [Glooscap] at para 4; International Charity Association
Network v Canada (National Revenue), 2008 FCA 114 at para 5). As the Federal
Court of Appeal makes no distinction between the principles developed for
interlocutory stays or for interlocutory injunctions, its observations on the
cumulative requirement of the three elements of the RJR-MacDonald test are
equally applicable in the context of injunctions, even though these were made
in the context of stays.
[102] That said, I agree that three prongs of the interlocutory injunction
test are interrelated and that the three factors should not be assessed in total
isolation from one another (University of California v I-Med Pharma Inc,
2016 FC 350 [I-Med Pharma I] at para 31; University of California
v I-Med Pharma Inc, 2016 FC 606 [I-Med Pharma II] at para 27, aff’d
2017 FCA 8; Geophysical Service Incorporated v Canada-Nova-Scotia Offshore
Petroleum Board, 2014 FC 450 [Geophysical Service] at para 35; Merck
& Co Inc v Nu-Pharm Inc, (2000) 4 CPR (4th) 464 [Nu-Pharm]
at para 13).
[103] In their written and oral submissions, the Plaintiffs relied on case
law developing the “blatant infringement” approach
to suggest that this may result in a lower irreparable harm threshold or even in
an exemption from the requirement to establish irreparable harm, depending on
the facts at stake. They argue that, in the circumstances of this case, the
behaviour of the Triforest Defendants amounts to a blatant patent infringement,
and they invite the Court to consider a more lenient approach on the issue of
irreparable harm.
[104] This line of jurisprudence on “blatant
infringement” must, however, be put in its proper context.
[105] First, I note that the “blatant
infringement” argument has arisen in copyright cases, as opposed to
patent cases. While it is well accepted that copyright infringement does not
take place inadvertently, this is not necessarily the case for patent
infringement given the highly technical nature of most patent claims. In fact,
in one of the early cases where the notion of “blatant
infringement” was introduced, Madam Justice Reed made an explicit
distinction with patent cases before accepting that there was a lesser need to
prove irreparable harm in “blatant” cases of
copyright infringement (International Business Corporation v Ordinateurs
Spirales Inc/Spirales Computers Inc (1984), 80 CPR (2d) 187 (FCTD) [Spirales
Computers] at 201). She explicitly indicated that for patent cases, the
threshold must be higher, and would require the usual proof of irreparable harm
for interlocutory injunctions:
In any event, I am not convinced that the
degree of harm required to be proved in a case such as this, where there had
been blatant copying, is as high as that required in other cases of
interlocutory injunction. Counsel for the plaintiff argued that the irreparable
harm test was appropriate to patents because it was easy to inadvertently
infringe a patent right. Thus, the courts are slow to grant interlocutory
injunctions in patent cases. He argued, however, that copying could not take
place inadvertently and therefore the courts were more willing to grant
interlocutory injunctions in copyright infringement actions when the copying
was very clear, without requiring irreparable harm or a finding that damages
would not be adequate. I accept this reasoning. It accords with my
interpretation of the jurisprudence.
[106] I am not aware of cases, and counsel for the Plaintiffs did not cite
any, where this notion of “blatant infringement”
was used in the context of an injunctive relief sought for patent infringement.
It is a concept which remains foreign to patent cases.
[107] Second, the “blatant infringement” cases
can be traced back to the reasoning of Mr. Justice Nadon in Diamant Toys Ltd
v Jouets Bo-Jeux Toys Inc, 2002 FCT 384 [Diamant Toys], where he
adopted the Court’s view in Spirales Computers and found that when copyright
infringement is blatant, there must be a less stringent test of damages (Diamant
Toys at para 56). However, as recently stated by Madam Justice
Tremblay-Lamer in Bell Canada v 1326030 Ontario Inc (iTVBox.net), 2016
FC 612 [Bell Canada], Mr. Justice Nadon’s reasoning has subsequently
been read by this Court as being restricted to those situations where there is
a finding of blatant copyright infringement (Bell Canada at para 29; Geophysical
Service at para 36; Western Steel and Tube Ltd v Erickson Manufacturing
Ltd, 2009 FC 791 [Western Steel] at paras 11-12).
[108] Third, these “blatant infringement” cases
did not go as far as suggesting or implying that no proof of irreparable harm
is required in order to obtain an interlocutory injunction when there is evidence
of blatant copyright infringement. In my view, they rather only hold for the
proposition that a strong finding on the first prong of the tripartite
injunction test in copyright cases may lower the threshold on the other two
prongs, and that it may then be appropriate to consider a less severe test of
potential damage than would otherwise be the case (Western Steel at para
12). I am not aware of injunction cases where an applicant’s case was sufficiently
strong, even in the copyright context, that the threshold for meeting the other
two factors was set so low that no proof of irreparable harm was required. A
robust case on the serious issue dimension of the RJR-MacDonald test does
not relieve the moving party from the burden of establishing that it would
suffer some irreparable harm that could not be compensated with damages (Bell
Canada at para 29). In short, “there is no
automatic conclusion that irreparable harm exists merely because the foundation
of an action is an infringement of copyright or trademark or the alleged tort
of passing off” (Western Steel at para 11).
[109] I further observe that, in cases where this issue of blatant copyright
infringement was raised, the Court was nonetheless persuaded that there was some
form of irreparable harm (Bell Canada at para 31). I mention one last
point: the early cases such as Diamant Toys where the “blatant infringement” approach emerged were not
interlocutory injunction cases but rather cases involving preservation orders,
where the legal requirements are different (Western Steel at paras
11-12).
[110] For all those reasons, I am not convinced that the “blatant infringement” case law should guide my
approach to the assessment of irreparable harm in this patent case, or that I
should depart from the well-accepted principles governing the evidentiary
requirements for this second element of the RJR-MacDonald test.
[111] In any event, even if I were to assume that there is precedent to
support the proposition that irreparable harm can be satisfied by a
demonstration that a defendant’s allegedly infringing patented product is
substantially the same as that of the plaintiff, and that the “blatant infringement” approach developed in the
copyright space could be imported into the patent space, I consider that the
evidence before me is inadequate and insufficient to make a determination that
there is a “blatant” patent infringement in this
case. A strong prima facie case of patent infringement does not
necessarily equate to a blatant infringement. To be qualified as blatant, the
infringement needs to be undeniable and unmistakable. I accept that such
obviousness can arise in copyright and trademark cases, but it is much more
difficult to establish in patent cases. Especially in a situation where, as is
the case here, the Triforest Defendants have raised some arguments questioning
the validity of the Plaintiffs’ Canadian Patents, where the patents cover
dozens of pages and each identify numerous claims, and where there is no
explicit admission of infringement. The issue will be debated in detail at
trial. While I agree that the Plaintiffs have a strong prima facie case
of patent infringement, I am not persuaded that the evidence before me suffices,
at this early stage, to qualify this case as one of “blatant
infringement” by the Triforest Defendants.
(2)
Serious issue
[112] The first part of the tripartite test is whether the evidence before
the Court is sufficient to satisfy it that there is a serious issue to be
tried. The threshold is a low one. While a preliminary assessment of the merits
of the case is required, “a prolonged examination of
the merits is generally neither necessary nor desirable” (RJR-MacDonald
at 337-338). As a general rule, the question of whether a serious issue exists
should be answered on the basis of no more than an “extremely
limited review of the case” (RJR-MacDonald at 348). Once the Court determines that the
underlying proceeding is “neither vexatious nor
frivolous”, it should proceed to the second part of the test (RJR-MacDonald
at 337). In an interlocutory injunction, “the
underlying dispute remains to be decided, and judges sitting on such matters
should generally avoid wading any further into that underlying dispute than is
strictly necessary to deal with the matter before them” (Jamieson
Laboratories Ltd v Reckitt Benckiser LLC, 2015 FCA 104 at para 25).
[113] In light of my earlier finding that the Plaintiffs have demonstrated
a strong prima facie case of patent infringement on the motion for an
interlocutory Mareva injunction, I am satisfied that there is a serious issue
to be tried. There is an initial presumption that the Canadian Patents of the
Plaintiffs are valid and based on the facts before me, there is definitely at
least an arguable case and a serious issue that the Defendants’ Unlicensed Products
would fall within the scope of one or more claims of the Canadian Patents. The
fact that the Defendants may have an arguable case of their own to question the
validity of the Canadian Patents does not mean that there is no serious issue
to be tried.
[114] The first element of the RJR-MacDonald test is accordingly
met.
(3)
Irreparable harm
[115] I now turn to the second part of the tripartite test, irreparable
harm.
(a)
Legal requirements
[116] “Irreparable”
refers to the nature of the harm suffered rather than its magnitude; it is harm
which “either cannot be quantified in monetary terms or
which cannot be cured” (RJR-MacDonald at 341). The threshold for
establishing irreparable harm is very high. Harm does not become irreparable
solely because precisely calculating damages would be difficult, as is
regularly the case in patent cases (I-Med Pharma II at para 32; Merck
Frosst Canada Inc v Canada (Minister of Health) (1997), 74 CPR (3d) 460 (FCTD)
[Merck Frosst Canada] at 464; Merck & Co v Apotex Inc, [1993]
FCJ No 1095 at para 42). Difficulty in precisely calculating damages does not
constitute irreparable harm, provided there is some reasonably accurate way of quantifying
and measuring those damages (Nu-Pharm at para 32).
[117] It is also well established that irreparable harm in the context of
injunctive relief must flow from clear and non-speculative evidence which
demonstrates how such harm will occur if the relief is not granted (AstraZeneca
Canada Inc v Apotex Inc, 2011 FC 505 at para 56, aff’d 2011 FCA 211; Aventis
Pharma SA v Novopharm Ltd, 2005 FC 815 [Aventis Pharma] at paras
59-61, aff’d 2005 FCA 390; Syntex Inc v Novopharm Ltd (1991), 36 CPR (3d)
129 (FCA) at 135). Simply finding that irreparable harm is likely is not enough;
there must be evidence that the moving party will or would suffer irreparable
harm if the injunction if not granted (Centre Ice Ltd v National Hockey
League at al (1994), 53 CPR (3d) 34 (FCA) [Centre Ice] at 52).
[118]
In Janssen, the Federal Court of Appeal
stated that a party seeking a suspension relief must demonstrate in a detailed
and concrete way that it will suffer “real, definite,
unavoidable harm – not hypothetical and speculative harm – that cannot be
repaired later” (Janssen at para 24). In that decision, Mr.
Justice Stratas added that “it would be strange if
vague assumptions and bald assertions, rather than detailed and specific
evidence, could support the granting of such serious relief” (Janssen
at para 24). The Federal Court of Appeal has indeed frequently insisted on the
quality of evidence needed to establish irreparable harm. General assertions cannot establish irreparable harm as “[t]hey essentially prove nothing” (Gateway City Church v Canada (National
Revenue), 2013 FCA 126 [Gateway Church] at para 15). Similarly, “[a]ssumptions, speculations, hypotheticals
and arguable assertions, unsupported by evidence, carry no weight” (Glooscap at para 31).
[119] I cannot do better than repeat the often-cited passage from Mr.
Justice Stratas in Stoney First Nation v Shotclose, 2011 FCA 232 [Stoney
First Nation] at para 48:
It is all too easy for those seeking a stay
in a case like this to enumerate problems, call them serious, and then, when
describing the harm that might result, to use broad, expressive terms that
essentially just assert – not demonstrate to the Court’s satisfaction – that
the harm is irreparable.
[120] In injunctive matters, the burden is on the moving
party to satisfy the court that there is “evidence at a convincing level of particularity that demonstrates a
real probability that unavoidable irreparable harm will result” unless the injunction is granted (Gateway Church at para 16;
Glooscap, at para 31; Stoney First Nation at para 48). Again, the
requirement of having evidence “sufficiently clear, convincing and cogent to satisfy the balance of
probabilities test”, set out in McDougall,
of course also applies to the clear and non-speculative evidence needed for
irreparable harm.
(b)
Plaintiffs’ claims of irreparable harm
[121]
The Plaintiffs argue that, if an interlocutory
injunctive relief preventing the Defendants from continuing to import and sell
the Unlicensed Products is not granted, they will suffer serious and
irreparable harm under a number of headings. These
allegations of harm are premised on the fact that Triforest is now amongst the
top five importers of laminate flooring products in Canada and that, to the
Plaintiffs’ knowledge, it is the largest importer of infringing laminate
flooring products.
[122] The Plaintiffs’ claims of irreparable harm are all contained in the
affidavit of Ms. Walmsley-Scott. No other evidence has been provided by the
Plaintiffs. In essence, Ms. Walmsley-Scott states that the Plaintiffs will suffer
harm through 1) the loss of goodwill and reputation; 2) the loss of market
share and of existing and potential customers; 3) the risk of the Defendants “springboarding” into the post-patent market; and 4) the
financial inability of the Defendants to pay an eventual judgment against them.
[123] I observe that Ms. Walmsley-Scott does not cite nor provide a single
document in support of her allegations of harm.
[124] Having reviewed the totality of the evidence provided by the
Plaintiffs, I am not satisfied that, on a balance of probabilities, there is the
required clear and non-speculative evidence to support any of the allegations
of irreparable harm. In fact, even if I were to assume that the current case could
amount to a “blatant infringement” and that the
lower threshold approach discussed above could be imported in the patent space,
I do not find that the Plaintiffs’ assertions of irreparable harm would meet
these more flexible requirements.
[125] First, the various allegations of harm are not supported by detailed
and specific evidence, and they thus remain in the universe of speculations. Second,
the harm alleged by the Plaintiffs is all quantifiable, and no expert evidence
has been provided to demonstrate that such harm is not measurable in monetary
terms or that no methodology is available to calculate the Plaintiffs’ alleged
damages.
(c)
Speculative nature of irreparable harm
[126] The alleged harm singled out in the affidavit of Ms. Walmsley-Scott
can be regrouped under four different headings.
(i)
Loss of goodwill and reputation
[127] The Plaintiffs first claim that if the infringement of their intellectual
property rights is allowed to continue, their goodwill and reputation will be hurt.
This will result from the impossibility of monitoring the Defendants’
infringement, the destruction of the goodwill built between the Unilin Group
and its licensees and importers of licensed products, and the incitement of
other importers to trade in unlicensed products.
[128] The Plaintiffs contend that the Unilin Group will be perceived in
the flooring industry as being unwilling and unable to enforce its Canadian
intellectual property rights and the L2C Program, despite the significant time
and resources it has spent on developing its program. Ms. Walmsley-Scott says
it will become impossible to monitor and prevent the infringing activities if
Triforest is not prevented from selling the Unlicensed Products, and that it is
already impossible for Unilin to properly monitor the situation. The Plaintiffs
also submit that the failure by the Triforest Defendants to pay royalties has
impaired the ability of other licensees to fairly compete in the Canadian marketplace,
thus undermining Unilin’s licensing program. The Plaintiffs further allege
that, if not restrained by this Court, the Defendants’ ongoing infringement
will incite other importers of laminate flooring products to purchase their
products from unlicensed manufacturers, and new manufacturers not to seek a license
from Unilin, the whole in order to avoid paying the royalties owed to Unilin for
the licensing of the products incorporating the Glueless Locking Technology.
[129] Ms. Walmsley-Scott affirms that this harm cannot be measured in
monetary terms.
[130] The problem is that, apart from Ms. Walmsley-Scott own self-serving
assertions, there is no evidence on the various components of this chain of
events. The risk of such harm is entirely speculative as these assertions are
unsupported by any evidence and any degree of particularity. The record
indicates that Triforest and Molson have been present in the Canadian market
for over two years and that Triforest has managed to become one of the five
leading importers of laminate flooring products in Canada. Yet, no particular evidence
has been provided by Ms. Walmsley-Scott or the Plaintiffs with respect to the
impact of the Defendants’ presence on the business of their licensees in
Canada, or of the Canadian importers of their licensed products.
[131] There is no evidence on the potential negative perceptions or
impossibility of monitoring. Also, no evidence from importers or from licensees
has been adduced to the effect that they might have a negative view on the
Plaintiffs’ monitoring and enforcement of its Canadian Patents. There is no
evidence of licensees having discontinued or threatening to discontinue paying
royalties to Unilin if the Triforest Defendants continue to operate their
business without having to pay theirs. There is also no evidence of potential
or prospective licensees refraining from doing business with Unilin while
awaiting the outcome of the Plaintiffs’ recourses against the Triforest
Defendants.
[132] This situation is quite different from the cases cited by the
Plaintiffs, such as Universal City Studios Inc v Zellers Inc (1983), 73
CPR (2d) 1 (FCTD) at 11 or Anne of Green Gables Licensing Authority Inc v
Avonlea Traditions Inc (2000), 6 CPR (4th) 57 (Ont CA) at
para 16, where some supporting evidence from license users had been provided on
the issue of loss of goodwill and reputation.
[133] Similarly, there is no evidence to substantiate the so-called floodgates
argument advanced by the Plaintiffs, as no particulars or examples (expect for
the statements made by Ms. Walmsley-Scott) have been provided showing that
other manufacturers or importers have been or could be encouraged to engage in
the infringing activities, resulting in a “death by
1000 cuts” to the Unlin Group’s licensing and L2C Program (Spirales
Computers at 199-200).
[134] The Plaintiffs bear the onus of providing the clear and convincing evidence
of irreparable harm to their goodwill and reputation, but their evidence on
this issue boils down to hypotheticals and speculations. No witness and no
document lend any support for the assertions made on this claim of reputational
damage. I must therefore conclude that the Plaintiffs have not established a
basis for this heading of irreparable harm.
[135] In addition, I am also not persuaded that the evidence supports the
allegation that it has been or will become impossible for the Plaintiffs to
monitor and prevent infringing activities if the injunction is not granted. I instead
note that the Plaintiffs’ own evidence shows that they have been somewhat
actively protecting and enforcing their patents relating to the Glueless
Locking Technology, including the Canadian Patents. The Plaintiffs have sent
over 200 letters to potential importers operating in Canada to notify them
regarding the LC2 Program and to flag the issue of potential infringement of
their intellectual property rights on laminate flooring products. The evidence
also indicates that the Plaintiffs keep track of sales of unlicensed products
in Canada. Finally, they have taken action and initiated a few lawsuits against
various alleged infringers, including recently against MGA. This behaviour is
not reflective of a patent owner unable to monitor and enforce its intellectual
property rights, or shackled in its efforts to do so.
(ii)
Loss of market share and of existing and
potential customers
[136] The Plaintiffs also claim that the infringing activities of the
Defendants will allow them to gain market share at the expense of Unilin’s
licensees, because unlicensed flooring products are sold by manufacturers at
lower prices than licensed products since no royalties are paid. This will also
result in manufacturers and importers being encouraged to sell unlicensed
products at a lower cost, and in a loss of actual or potential customers for
the Plaintiffs. The Plaintiffs further contend that, if the Defendants are
permitted to maintain their infringing activities, they will be able to
continue to unfairly compete with competitors selling licensed laminate
flooring products in Canada, including Unilin and customers of Unilin’s
licensees, by either charging lower prices for their products and/or using the
larger profits to invest in other activities to increase sales.
[137] This, repeats Ms. Walmsley-Scott, cannot be estimated or measured in
monetary terms either.
[138] Again, the evidence provided only shows general and speculative
assertions about loss of market share, without any particularity. This, as the
Federal Court of Appeal frequently reminded, is insufficient to meet the high
threshold of irreparable harm.
[139] There is no evidence of new manufacturers refraining from seeking a
license from Unilin in order to avoid paying royalties, or threatening to do
so. Let alone evidence of such behaviour being triggered by the infringing
activities of the Defendants. There is no evidence of Unilin licensees having
terminated or threatening to terminate their licensing arrangements, of
licensees or importers having lowered or threatening to lower prices for their
licensed products. There is no evidence of lost sales or threat by importers to
purchase cheaper, unlicensed imported products. There is no evidence of other
manufacturers being tempted or encouraged to sell unlicensed products at a
lower cost, or of Unilin’s licensees losing actual or potential customers to
unlicensed manufacturers. There is not even evidence of Triforest’ Unlicensed Products
being sold at prices lower or with larger profits than the Unilin licensed
products because of the alleged monetary benefit gained from the failure to pay
royalties. Not a single sales report, example of lost business, testimony of
licensee or of importer has been offered to support the allegations made by Ms.
Walmsley-Scott.
[140] In that context, to suggest that there could be irreparable harm in
the form of lost sales or lost customers in the period leading to the hearing
on the merits is entirely speculative. The unsubstantiated affirmations of Ms.
Walmsley-Scott cannot base a finding of irreparable harm. In fact, at one
point, Ms. Walmsley-Scott even says that, since it is difficult to get back a
customer’s business once it is lost, this may result in some of Unilin’s
licensees going out of business due to an inability to compete. This falls
short of the requirements established by the case law on irreparable harm.
[141] Again, despite the fact that the Plaintiffs have known about the
allegedly infringing activities of the Defendants since at least August 2014
and monitored Triforest’s importation activity using publicly accessible data
from Datamyne, they offer no concrete evidence to support any loss of business
during this period, or that other importers of laminate flooring products have
purchased their products from unlicensed manufacturers.
[142] This is a case where the party seeking to enforce its patents was in
the market at the same time as the alleged infringer and, as the Federal Court
of Appeal reminded in Centre Ice, a notable absence of supporting evidence
of lost business in those circumstances is fatal to a claim of irreparable harm
(Centre Ice at 54). I would add that this Court has frequently held that
this type of harm alleged to be suffered by the Plaintiffs in terms of lost
market share, lost opportunities to expand and price reductions is typically not
irreparable in patent cases (I-Med Pharma II at paras 43-46; Aventis
Pharma at paras 33-45; Merck Frosst Canada at 462).
[143] In any event, if that was to translate into an ability for the
Defendants to obtain a greater market share than they would otherwise have been
able to have, to the detriment of competitors who respect intellectual property
rights and acquire products from licensed manufacturers, this damage would be quantifiable
as it would take the form of increased sales of unlicensed products for which
royalties need to be paid to Unilin.
(iii)
Springboarding
[144] The Plaintiffs further raise the prospect of irreparable harm
resulting from “springboarding”. The “springboard” argument refers to situations where the alleged
infringer has not yet entered the market but plans to do so near the end of the
patent life, or where the alleged infringer actually enters the market, in
order to gain an early start or position to better compete in the after-patent
market. The party holding the patent thus loses a part of the market share due
to a breach of its patent in anticipation of the patent’s expiry (China
Ceramic Proppant Ltd v Carbo Ceramics Inc, 2004 FCA 283 at paras 3 and 10).
Springboarding thus typically refers to losses intervening after the expiry of
the patent, caused by a behaviour that, however, occurred prior to the expiry (Bayer
Healthcare AG v Sandoz Canada Incorporated, 2007 FC 352 [Bayer] at
para 52).
[145] Given that the 076 Patent and the 321 Patent will expire in June
2017, the Plaintiffs claim that the Defendants’ ongoing infringement of Unilin’s
patent rights until their term will provide them with the ability to obtain a
greater market share than they would otherwise have been able to secure through
selling licensed products, and provide the Defendants with a “springboard” into the post-patent market (Baker
Hughes Inc v Galvanic Analytical Systems Ltd (1991), 37 CPR (3d) 512 (FCTD)
at 515; Spirales Computers at 199-200). That is, the advantage gained by
the Triforest Defendants as a result of their premature entry into the market
will continue to result in losses for Unilin in the months immediately
following the expiry of the Canadian Patents, which damages, the Plaintiffs say,
are not recoverable.
[146] I do not find that, in light of the evidence before me, this “springboarding” amounts to demonstrated irreparable
harm to the Plaintiffs. First, it is true that Unilin’s Canadian Patents are approaching
the end of their term of protection but, since the Defendants are already on
the market and are not new players planning a “springboard”
entry, I am not convinced that there is clear and non-speculative evidence of
harm in that respect in the existing market context. As indicated above, the
Plaintiffs have failed to provide the required convincing and non-speculative evidence
of loss of market share despite the Plaintiffs’ awareness of the Triforest
Defendants’ activities since more than two years.
[147] Second, since the Plaintiffs are not directly present in the
Canadian market except through the sales of their licensed products made by
importers and the receipt of royalties, how can there be harm to the Plaintiffs
in terms of lost market opportunities following the expiry of the Canadian Patents?
That would be harm to the business of Unilin’s licensed manufacturers or of
importers of its licensed products, which would allegedly lose ground to the
Triforest Defendants in the after-patent market. Only harm suffered by the
moving party qualifies under this branch of the RJR-MacDonald test, not
that of third parties (Glooscap at para 33). The Plaintiffs thus cannot
claim these potential losses of their importers or licensees in the post-patent
market as irreparable harm of their own. In addition, this claim of potential
loss remains hypothetical and suffers from the same shortcomings identified
above on the lack of particularity.
[148] Third, I am also not persuaded that this type of harm cannot be
measured in monetary terms for the Plaintiffs, as it will essentially translate
into loss of royalty revenues until the expiry of the patent protection (Aventis
Pharma at para 61; Bristol Myers Squibb Co v Apotex Inc, 2001 FCT
1086 at paras 20-21). Damages in patent cases are intended to put a successful plaintiff
in the position that it would have been in, but for the infringement. It is
entirely speculative to say that a party will not be able to recover damages
for any losses that it may suffer in the post-patent period, as such damages can
indeed be recoverable and calculable (Bayer at paras 56-57).
(iv)
Inability to pay
[149] The Plaintiffs finally claim that, based on Unilin’s prior
experience in being denied proper compensation by MGA following MGA’s
infringement of its patent rights in Canada, there is a genuine risk that
Unilin would not be able to recover the complete damages owed by the Defendants
as a result of their similar infringing activities. Ms. Walmsley-Scott states
that she believes “that Triforest will attempt to
thwart any order of this Court through a similar scheme” (as MGA). In
relation to that concern over the Defendants’ inability to pay, the Plaintiffs also
rely on the October 2015 events detailed above. They argue that the Triforest Defendants
have explicitly stated and shown that they had no intention to pay Unilin the
royalties owed for the unlicensed laminate flooring products they had imported at
the time and continue to import, and that, if Triforest were to be forced to do
so, their only option would be to go bankrupt. In light of the fact that
Triforest explicitly stated that it would be financially unable to pay the
license fees for the unlicensed products they have imported, the Plaintiffs
submit that it is absolutely reasonable to conclude that Triforest will not pay
the damages they would be ordered to pay by the Court.
[150] I do not agree that this amounts to clear and non-speculative
evidence of irreparable harm in the circumstances of this case.
[151] I first note that this inability to pay has not been recognized as
irreparable harm in Eli Lilly, since a failure to be able to collect a
judgment is speculative. It is speculative with respect to the monetary amount
at stake as the moving party does not know what will not be available from the defendant
in the event it is successful in its action for infringement. This is precisely
the case here. The Plaintiffs have only established that they are concerned to
be unable to collect on a future judgment against the Triforest Defendants.
This does not satisfy the irreparable harm requirements (Eli Lilly at
para 32). The Plaintiffs must establish the harm with clear and convincing
evidence and demonstrate on a balance of probabilities that the alleged harm is
likely to occur. The Plaintiffs’ potential failure to be able to collect a
judgment meets none of these requirements as the Plaintiffs can only speculate
as to the amount of damages they say that they may fail to recover (Eli
Lilly at para 32; RBC Dexia Investor Services Trust v Goran Capital Inc,
2016 ONSC 1138 at para 11).
[152] That said, I acknowledge that some cases suggest that a real,
non-speculative risk of a defendant’s financial inability to satisfy a judgment
or an award could, in certain circumstances, be a relevant consideration in the
assessment of the question of irreparable harm (RJR-MacDonald at 341; Turbo-Resources
Ltd v Petro-Canada Inc (1989), 24 CPR (3d) 1 (FCA) at 18-19). Even if I was
to follow this line of cases, for a defendant’s inability to pay to constitute irreparable
harm, there would still need to be, as always, clear and non-speculative evidence
demonstrating such inability on a balance of probabilities. I am not persuaded
that the evidentiary record before me supports such a conclusion in this case.
[153] The Plaintiffs have the evidentiary burden of establishing that the
Defendants’ current financial situation is such that the Plaintiffs would not
be able to collect on damages which may be awarded to them if successful. I can
appreciate that Ms. Walmsley-Scott and the Plaintiffs feel some frustration
following the recent experience they went through in the aborted enforcement of
their rights against another infringer, MGA, due to MGA’s filing for bankruptcy.
However, to draw from this separate and unrelated event a claim of irreparable
harm based on a suspected parallel behaviour by the Defendants is entirely
speculative.
[154] I further note that the statement attributed to Triforest to the
effect that they would be financially unable to pay the Unilin license fees was
made in October 2015, and that the information available on the financial
situation of the Triforest Defendants since then does not reflect that they are
in financial difficulty. On the contrary, there is no evidence of dissipation
of assets, bankruptcy, collections or judgment against the Defendants in the
results of the financial investigations conducted by the Plaintiffs and filed
in support of their Review Motion. As previously discussed, the Plaintiffs’
investigation shows that the bank accounts, loans, mortgages, credit cards and
leases of the Triforest Defendants are in good standing, and that the three
individual Defendants recently acquired Canadian real estate assets. Furthermore,
the banking accounts evidence obtained further to the execution of the Mareva
Injunction Order shows that the Triforest Defendants hold many banking accounts
containing substantial balances in December 2016.
[155] I therefore do not find, after weighing the various elements of the
evidentiary record before me and on a balance of probabilities, that the
Plaintiffs’ sour collection experience with MGA or the October 2015 statement
of Triforest’s representatives suffice to conclude that there is clear and
non-speculative evidence of an inability to pay on the part of the Defendants, cogent
enough to qualify as irreparable harm. The suggestion that the Defendants would
not be in a financial position to pay whatever amount of damages might be awarded
to the Plaintiffs at trial does not find support in the evidence in the
circumstances. In other words, doubts or concerns that a plaintiff may have
about a defendant’s eventual incapacity to pay are not enough to grant an interlocutory
injunction pending trial.
[156] To demonstrate that harm will actually be suffered and that it will
not be able to be repaired later, the moving party must provide evidence
concrete and particular enough to allow the Court to be persuaded on the matter
(Stoney First Nation at para 49). Injunctive relief is not granted on
the basis of assertions, it is granted on the basis of evidence. And this is
what is lacking here.
(v)
Conclusion on speculative nature of harm
[157] In light of the foregoing, I am not convinced that the Plaintiffs
have adduced the required real, clear and non-speculative evidence showing that
they will suffer irreparable harm. There is no persuasive, detailed and
concrete evidence demonstrating the existence of the various headings of potential
harm asserted by Ms. Walmsley-Scott. I thus find that the various allegations cannot
support a finding of irreparable harm meeting the requirements established by RJR-MacDonald
and its progeny. As was the case in Janssen, the harm that the
Plaintiffs say they might potentially suffer is too speculative and
hypothetical to form a basis for a finding of irreparable harm.
[158] It is entirely understandable that, given the context of this dispute,
the Plaintiffs are concerned and fear that, absent an injunctive restraint on
the Defendants, they will continue to suffer lost revenues from unpaid
royalties by the Defendants, what they feel is a loss of goodwill and other
adverse impacts. However, these fears need an objective basis in order to
qualify as irreparable harm and to open the door to an exceptional
interlocutory injunctive relief. The central problem with the Plaintiffs’ claims
of irreparable harm is that they are unsupported by evidence beyond the
assertions of Unilin’s main corporate witness. “Irreparable
harm must be demonstrated, not just asserted. Demonstration is achieved by
supplying particular information that empowers the Court to find the existence
of harm that cannot be repaired later” (Gateway Church at para
18). On the record before me, there is only assertion, not demonstration.
(d)
Quantifiable nature of harm
[159] There is also a second major problem with the Plaintiffs’
allegations of irreparable harm, and it is the fact that the evidence on the
record does not allow to conclude that the alleged harm is not quantifiable,
and thus irreparable.
[160] Ms. Walmsley-Scott states on a few occasions that the damages apprehended
by the Plaintiffs cannot be measured in monetary terms. These bald statements
fall short of the exigencies of irreparable harm in two main respects. First, no
credible and convincing evidence has been provided to support the assertions
that the Plaintiffs’ harm would be impossible to quantify in monetary terms. Second,
there is every indication on the record that damages in respect of any royalty
revenues lost or likely to be lost by Unilin are indeed capable of calculation.
[161] As rightly pointed out by counsel for Molson at the hearing, an
affirmation from Ms. Walmsley-Scott to the effect that the Plaintiffs’ alleged
harm is not quantifiable in monetary terms is not good enough. Ms.
Walmsley-Scott is a corporate witness who does not have the experience nor the
expertise to render an “opinion on what is quantifiable
in damages and what is not” (I-Med Pharma I at para 39). Furthermore,
Ms. Walmsley-Scott offers no factual basis for her assertions on the incapacity
to measure the alleged damages. I agree with the Defendants that such evidence
is not sufficient and falls well short of having the attributes able to
convince me that, on a balance of probabilities, the claimed harm is not
quantifiable in monetary terms (I-Med Pharma I at paras 36-44).
[162] No proper expert evidence on the record speaks to quantification
issues, neither on why the alleged damages of the Plaintiffs cannot be
quantified and measured in monetary terms, nor on why no methodology exists to
calculate them. This is quite different from the situation in Reckitt
Benckiser LLC v Jamieson Laboratories Ltd, 2015 FC 215 [Jamieson] at
paras 53-54, aff’d 2015 FCA 104 at para 31, where losses were considered
irreparable because there was extensive expert evidence demonstrating that no
possibility of quantifying the losses and of calculating the damages existed.
[163] Contrary to the situation in Jamieson, no attempt was even made
by the Plaintiffs to try to quantify the alleged harm. And no expert evidence
was provided to support the assertion that the Plaintiffs’ damages are not
capable of quantification or to demonstrate that no methodology for quantifying
the losses exists. I just cannot infer that damages cannot be quantified in
monetary terms from the unsupported allegations of a corporate witness who is
not in a position to address the quantification issue.
[164] I add that damages are not unquantifiable simply because there could
be some difficulty in calculating them (Nu-Pharm at para 32). “Patent rights are economic in nature and there is usually no
reason why damages ensuing from infringement are unable to be measured or
calculated in a reasonably accurate way” (I-Med Pharma II at para
79; Pfizer Ireland Pharmaceuticals v Lilly Icos LLC, 2003 FC 1278 at
para 27 citing Cutter Ltd v Baxter Travenol Laboratories of Canada Ltd
(1980), 47 CPR (2d) 53 (FCA) at 55-56). It is the burden of the moving party to
demonstrate that damages cannot be quantified when it alleges that this is the
case. The Plaintiffs have failed to do so here.
[165] Superimposed on this is the fact that there is every indication that
the damages claimed by the Plaintiffs to be irreparable are in fact
quantifiable. The harm to be suffered by the Plaintiffs further to the alleged
patent infringement by the Defendants results from lost licensing revenues and
lost royalties. The Plaintiffs do not themselves sell the laminate flooring
products at issue in the Canadian market; only importers selling Unilin’s
licensed products do. The Plaintiffs rather collect royalties under
non-exclusive licensing agreements with approximately 49 importers operating in
the Canadian market. The Plaintiffs’ royalties and license fees are based on a
simple formula using the volume of laminated flooring products sold.
[166] Based on the evidence, this looks to be easily capable of
quantification. Indeed, the Plaintiffs have been able to estimate lost
licensing revenues in their written submissions. For example, using publicly
accessible data of Triforest’s import activity, the Plaintiffs have quantified
a reasonable royalty of $228,000 on inventory currently in Triforest’s
possession, using the square meterage (m2) of these products multiplied by the
royalty rate of $US 0.92 per m2 adjusted by the exchange rate of $1.33/$US. For
past sales, a reasonable royalty can thus easily be calculated. Using the same
simple arithmetic, the Plaintiffs were also able to quickly make a damage
assessment and to estimate the lost royalties for past importation by the
Defendants in the conclusions contained in the revised proposed order they submitted
to the Court at the hearing of their Review Motion. Again, this figure was computed
based on square meterage of sales multiplied by the royalty rate.
[167] I should mention that there is nothing extraordinary about the type
of harm alleged – loss of goodwill, loss of market share, incitement of others
to infringe – that would differentiate this case from most patent infringement
proceedings. The loss of licensing fees which may be owed are quantifiable
damages which can reasonably be determined after a decision on the merits of
the case.
[168] For all those reasons, I am therefore not satisfied that the
Plaintiffs have offered sufficient evidence demonstrating, on a balance of
probabilities, that they would suffer harm that is irreparable, if the interlocutory
injunction is not granted. The allegations and evidence before me do not amount
to clear and non-speculative evidence establishing harm and allowing the Court
to make inferences that the claimed harm is not quantifiable and thus
irreparable. The second element of the RJR-MacDonald test is accordingly
not met.
(4)
Balance of convenience
[169] I now turn to the last part of the RJR-MacDonald test, the
balance of convenience (or inconvenience, as some prefer to state it). Under
this third part of the test, the Court must determine which of the parties will
suffer the greater harm from the granting or refusal of the interlocutory
injunction, pending a decision on the merits (RJR-MacDonald at 342).
Given that the Plaintiffs have not led the evidence needed to allow me to make
a finding of irreparable harm and having concluded that they have failed to
satisfy that branch of the RJR-MacDonald test, it is not necessary for
me to consider where the balance of convenience lies. The Plaintiffs’ motion
succeeds only if all three requirements are proved, and one of the elements has
clearly not been established.
[170] Since the three components of the test are interrelated, I would
however add that, in my view, the balance of convenience favours the Defendants
as refusing the issuance of an interlocutory injunction implies that the status
quo will be maintained until a decision on the merits of the Plaintiffs’
action for patent infringement, and that the Defendants will continue to carry
on their business in the interim period. Moreover, if an interlocutory
injunction is refused, the Plaintiffs have not established that they will
suffer irreparable harm, and damages will remain a remedy available and
adequate for the unpaid royalties that could be owed by the Defendants.
(5)
Conclusion on the interlocutory injunction
[171] The Plaintiffs have the obligation to satisfy me that they meet all
elements of the tripartite conjunctive test set forth in RJR-MacDonald
in order to be successful on their motion for interlocutory injunction. On the
basis of the evidence before me, I find that they have not provided clear and
non-speculative evidence of irreparable harm, and that the balance of
convenience does not favour them. I must therefore deny their motion.
D.
Other remedies
[172] Both the Plaintiffs and the Defendants seek a confidentiality order
with respect to certain affidavits containing banking information and financial
information on the Triforest Defendants. The evidence uncovered through the
execution of the Mareva Injunction Order and filed with the Court as exhibits
to the affidavits of Ms. Morin and Ms. Luong, as well as the affidavits of Ms.
Zhang and Mr. Wang, contain financial information pertaining to the Triforest
Defendants, including account numbers, transaction history and current
balances.
[173] In the circumstances, I am satisfied that this evidence should be
filed under seal and be subject to a confidentiality order in accordance with
Rule 151. I consider this to be appropriate on the basis of the principles in Sierra
Club of Canada v Canada (Minister of Finance), 2002 SCC 41 at paras
53-55 and the submissions of the parties.
IV.
Conclusion
[174] For the reasons detailed above, I conclude that the Mareva
Injunction Order was lawfully executed in accordance with its terms and
followed the applicable procedural rules. However, I am not persuaded that the
grounds required for the issuance of an interlocutory Mareva injunction order
are met, as the evidence obtained and provided by the Plaintiffs is not
sufficient to demonstrate, on a balance of probabilities, that there is a real
risk of removal or dissipation of assets by the Triforest Defendants in order
to frustrate judgment, outside the normal scope of their business. I am also
not satisfied that the tripartite test set forth in RJR-MacDonald for
the issuance of interlocutory injunctions is met, as the Plaintiffs have failed
to provide the required clear and non-speculative evidence to demonstrate, on a
balance of probabilities, that they will suffer irreparable harm if the
injunction is not granted.
[175] Costs are awarded to the Plaintiffs on their motion for the ex
parte Mareva Injunction Order and on the first dimension of their Review
Motion dealing with the review of the execution of the Order. Costs are awarded
to the Defendants on the two other aspects of the Plaintiffs’ Review Motion,
namely the motion for an interlocutory Mareva injunction and the motion for an
interlocutory injunction.